AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26222126 — intervention group
Group type: COMPARATOR
Intervention: EPA-E 1.8 g/day
Number of subjects: 210
Study 23277248 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (30 mg)
Number of subjects: 62
Study 23277248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT)
Number of subjects: 62
Study 23277248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 23277248 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 62
Study 21502572 — intervention group
Group type: EXPERIMENTAL
Intervention: Revacept 10 mg
Number of subjects: 30
Study 21502572 — intervention group
Group type: EXPERIMENTAL
Intervention: Revacept 20 mg
Number of subjects: 30
Study 21502572 — intervention group
Group type: EXPERIMENTAL
Intervention: Revacept 40 mg
Number of subjects: 30
Study 21502572 — intervention group
Group type: EXPERIMENTAL
Intervention: Revacept 80 mg
Number of subjects: 30
Study 21502572 — intervention group
Group type: EXPERIMENTAL
Intervention: Revacept 160 mg
Number of subjects: 30
Study 21502572 — intervention group
Group type: COMPARATOR
Intervention: Control (no Revacept)
Number of subjects: 30
Study 19814947 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 46
Study 19814947 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 46
Study 19814947 — intervention group
Group type: EXPERIMENTAL
Intervention: Both (Olanzapine and Risperidone)
Number of subjects: 46
Study 16332417 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing 20 microg ethinyl estradiol plus 0.15 mg desogestrel
Number of subjects: 15
Study 16332417 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing 0.100 mg levonorgestrel
Number of subjects: 15
Study 16332417 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing 0.75 mg of gestodene
Number of subjects: 15
Study 16332417 — intervention group
Group type: COMPARATOR
Intervention: Oligomenorrhoic untreated women
Number of subjects: 15
Study 12908665 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation 'atypical' antipsychotics
Number of subjects: 0
Study 12908665 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 0
Study 11103221 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml grape-skin extract in water (1 mg extract/ml) at each of three daily meals (31.3 mg total phenolics, including 9.0 mg catechin)
Number of subjects: 15
Study 11103221 — intervention group
Group type: COMPARATOR
Intervention: Experimental diet without grape-skin extract
Number of subjects: 15
Study 11103221 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape-skin extract intervention
Number of subjects: 15
Study 9200766 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian forecasting model for patients with cirrhosis
Number of subjects: 0
Study 9200766 — intervention group
Group type: COMPARATOR
Intervention: Bayesian forecasting model for patients without cirrhosis
Number of subjects: 0
Study 8267433 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-coated chest drainage tubes
Number of subjects: 102
Study 8267433 — intervention group
Group type: COMPARATOR
Intervention: Noncoated chest drainage tubes
Number of subjects: 102
Study 3535358 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-methyldopa
Number of subjects: 40
Study 3535358 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 31377190 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (EG)
Number of subjects: 151
Study 31377190 — intervention group
Group type: COMPARATOR
Intervention: Placebo-like stretching (PG)
Number of subjects: 151
Study 31377190 — intervention group
Group type: COMPARATOR
Intervention: Rest (RG)
Number of subjects: 151
Study 30049591 — intervention group
Group type: EXPERIMENTAL
Intervention: Three phlebotomies (every 3 weeks) and lipid‐lowering dietary counseling
Number of subjects: 86
Study 30049591 — intervention group
Group type: COMPARATOR
Intervention: Lipid‐lowering dietary counseling
Number of subjects: 86
Study 27188329 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) plus Methotrexate (MTX)
Number of subjects: 594
Study 27188329 — intervention group
Group type: COMPARATOR
Intervention: Traditional DMARD therapy
Number of subjects: 594
Study 27188329 — intervention group
Group type: EXPERIMENTAL
Intervention: SAA levels
Number of subjects: 594
Study 27188329 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease activity score of 28 joints (DAS28) using SAA levels
Number of subjects: 594
Study 24769123 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current stimulation (IFC)
Number of subjects: 30
Study 24769123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22252346 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% feed restriction on d 4, 5, and 6 plus 1,500 mg/kg of quercetin (FR60Q)
Number of subjects: 0
Study 22252346 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% feed restriction on d 4, 5, and 6 (FR60)
Number of subjects: 0
Study 22252346 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum feeding (control)
Number of subjects: 0
Study 19836899 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (SD)
Number of subjects: 7
Study 19836899 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Sleep Deprivation (4.5h of sleep)
Number of subjects: 7
Study 19836899 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular Sleep (7h of sleep)
Number of subjects: 7
Study 18033957 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 0
Study 18033957 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine 200 mg once daily
Number of subjects: 0
Study 15675976 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 18
Study 15675976 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 18
Study 12105164 — intervention group
Group type: EXPERIMENTAL
Intervention: EP-guided therapy with ICD
Number of subjects: 0
Study 12105164 — intervention group
Group type: COMPARATOR
Intervention: EP-guided therapy without ICD
Number of subjects: 0
Study 10544403 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue filters
Number of subjects: 113
Study 10544403 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal filters
Number of subjects: 113
Study 10544403 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo filters
Number of subjects: 113
Study 10544403 — intervention group
Group type: COMPARATOR
Intervention: Control group (no filters)
Number of subjects: 113
Study 8786248 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (treadmill walking, stair climbing, or both, 3 times per week for 40 minutes at 70-85% of maximal heart rate reserve for 16 weeks)
Number of subjects: 43
Study 8786248 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control
Number of subjects: 43
Study 8786248 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 43
Study 8786248 — intervention group
Group type: COMPARATOR
Intervention: Endurance training and Non-exercising control
Number of subjects: 43
Study 2184848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG fermented yoghurt
Number of subjects: 16
Study 2184848 — intervention group
Group type: COMPARATOR
Intervention: Pasteurized regular yoghurt (placebo)
Number of subjects: 16
Study 7407022 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphasia type (4 levels)
Number of subjects: 50
Study 7407022 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy (4 levels)
Number of subjects: 50
Study 7407022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexico-syntactic abilities (2 levels)
Number of subjects: 50
Study 31559966 — intervention group
Group type: EXPERIMENTAL
Intervention: T14 (triple therapy for 14 days; lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, all given twice daily)
Number of subjects: 1620
Study 31559966 — intervention group
Group type: EXPERIMENTAL
Intervention: C10 (concomitant therapy for 10 days; lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily)
Number of subjects: 1620
Study 31559966 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ10 (bismuth quadruple therapy for 10 days; bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day)
Number of subjects: 1620
Study 28079023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 647
Study 28079023 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 647
Study 28079023 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 647
Study 25476726 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 6
Study 25476726 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 6
Study 25476726 — intervention group
Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope
Number of subjects: 6
Study 23717424 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored education package consisting of multimedia falls prevention information with trained health professional follow-up
Number of subjects: 50
Study 23717424 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 21107998 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking tobacco and/or cannabis
Number of subjects: 744
Study 21107998 — intervention group
Group type: EXPERIMENTAL
Intervention: Using both substances (tobacco and cannabis)
Number of subjects: 744
Study 21107998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis and tobacco use
Number of subjects: 744
Study 21107998 — intervention group
Group type: EXPERIMENTAL
Intervention: Disordered eating, depressive symptoms, and cannabis use
Number of subjects: 744
Study 19694599 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth (TH), n = 70
Number of subjects: 138
Study 19694599 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC), n = 68
Number of subjects: 138
Study 17957097 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux dialyzer (polyamide)
Number of subjects: 20
Study 17957097 — intervention group
Group type: COMPARATOR
Intervention: Low-flux dialyzer (cuprophan)
Number of subjects: 20
Study 17957097 — intervention group
Group type: COMPARATOR
Intervention: Switching from low-flux to high-flux dialyzers
Number of subjects: 20
Study 15014297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg every 6 h until 36 h after defervescence)
Number of subjects: 80
Study 15014297 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (12 mg/kg every 6 h until 36 h after defervescence)
Number of subjects: 80
Study 11716884 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy (20 Gy in ten daily fractions over 2 weeks with 500 mg/m(2) fluorouracil intravenously on days 1‐3, repeated after 2 weeks)
Number of subjects: 541
Study 11716884 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (intravenous fluorouracil 425 mg/m(2) and folinic acid 20 mg/m(2) daily for 5 days, monthly for 6 months)
Number of subjects: 541
Study 9150709 — intervention group
Group type: EXPERIMENTAL
Intervention: Males aged 14-23 years
Number of subjects: 634
Study 9150709 — intervention group
Group type: EXPERIMENTAL
Intervention: Females aged 14-23 years
Number of subjects: 634
Study 8175136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (14 mg/kg/body wt/day)
Number of subjects: 222
Study 8175136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 3330593 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin (single 400 mg dose)
Number of subjects: 55
Study 3330593 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim (single 600 mg dose)
Number of subjects: 55
Study 31764775 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized intervention (antenatal breastfeeding education and postnatal lactation support)
Number of subjects: 352
Study 31764775 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 352
Study 29508247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 15 mg twice daily plus capecitabine 2000 mg/m2/day (Days 1-14)
Number of subjects: 407
Study 29508247 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus capecitabine
Number of subjects: 407
Study 27253708 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral SLR
Number of subjects: 10
Study 27253708 — intervention group
Group type: COMPARATOR
Intervention: Sham SLR
Number of subjects: 10
Study 25437218 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of the freshest available red blood cells (RBCs) until hospital discharge
Number of subjects: 5000
Study 25437218 — intervention group
Group type: COMPARATOR
Intervention: Standard-care red blood cells
Number of subjects: 5000
Study 22994054 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Xuanju Capsule plus tamoxifen citrate
Number of subjects: 120
Study 22994054 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen citrate alone
Number of subjects: 120
Study 20194828 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment for 12 weeks, titrated by clinical response
Number of subjects: 217
Study 20194828 — intervention group
Group type: COMPARATOR
Intervention: Baseline neuropsychological factors
Number of subjects: 217
Study 17592912 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (3-5 grams per day)
Number of subjects: 12
Study 17592912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15787865 — intervention group
Group type: COMPARATOR
Intervention: Oral cetirizine 0.25 mg/kg twice daily for 18 months
Number of subjects: 343
Study 12455075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB) angioplasty
Number of subjects: 180
Study 12455075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB) angioplasty for noncalcified lesions
Number of subjects: 180
Study 12455075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB) angioplasty for calcified lesions
Number of subjects: 180
Study 12455075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB) angioplasty with dissections in calcified lesions
Number of subjects: 180
Study 12455075 — intervention group
Group type: COMPARATOR
Intervention: Balloon Angioplasty (BA)
Number of subjects: 180
Study 10516774 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 MIU recombinant interferon alfa-2a
Number of subjects: 97
Study 10516774 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.0 MIU recombinant interferon alfa-2a
Number of subjects: 97
Study 10516774 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 97
Study 7669239 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM mothers breastfeeding
Number of subjects: 19
Study 7669239 — intervention group
Group type: COMPARATOR
Intervention: Non-IDDM mothers breastfeeding
Number of subjects: 19
Study 7669239 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM mothers delivered by Caesarean section
Number of subjects: 19
Study 7669239 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM mothers delivered earlier
Number of subjects: 19
Study 7669239 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM babies admitted to special care nursery
Number of subjects: 19
Study 2258894 — intervention group
Group type: EXPERIMENTAL
Intervention: co-dergocrine mesilate/nifedipine (4 mg/40 mg once daily)
Number of subjects: 40
Study 2258894 — intervention group
Group type: COMPARATOR
Intervention: mefruside/nifedipine (25 mg/40 mg once daily)
Number of subjects: 40
Study 7422046 — intervention group
Group type: EXPERIMENTAL
Intervention: Local throat analgesia
Number of subjects: 316
Study 7422046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation
Number of subjects: 316
Study 7422046 — intervention group
Group type: COMPARATOR
Intervention: No specific preparation
Number of subjects: 316
Study 30261805 — intervention group
Group type: EXPERIMENTAL
Intervention: Telementoring sessions through the TelePain programme
Number of subjects: 41
Study 30261805 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telementoring)
Number of subjects: 41
Study 31303184 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) with 6 mg Fe plus fourteen micronutrients
Number of subjects: 1704
Study 31303184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1704
Study 28215131 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (ANGII)
Number of subjects: 300
Study 28215131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 26297092 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy-assessed QOL-AD
Number of subjects: 0
Study 26297092 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject-assessed QOL-AD
Number of subjects: 0
Study 26297092 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy-assessed HUI-3
Number of subjects: 0
Study 26297092 — intervention group
Group type: EXPERIMENTAL
Intervention: HUI-3
Number of subjects: 0
Study 24200407 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 150
Study 24200407 — intervention group
Group type: COMPARATOR
Intervention: Prolonged conservative treatment
Number of subjects: 150
Study 21625270 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg once daily for 6 months
Number of subjects: 75
Study 21625270 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 6 months
Number of subjects: 75
Study 19076190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL)
Number of subjects: 0
Study 19076190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet B light therapy (UVB)
Number of subjects: 0
Study 19076190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PDL and UVB
Number of subjects: 0
Study 19076190 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study 17768502 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced indoor air pollution intervention
Number of subjects: 100
Study 17768502 — intervention group
Group type: COMPARATOR
Intervention: Fieldworker diagnosis of ALRI
Number of subjects: 100
Study 17768502 — intervention group
Group type: COMPARATOR
Intervention: Physician diagnosis of ALRI
Number of subjects: 100
Study 14963464 — intervention group
Group type: EXPERIMENTAL
Intervention: sildenafil 50 mg
Number of subjects: 43
Study 14963464 — intervention group
Group type: COMPARATOR
Intervention: apomorphine 2 mg
Number of subjects: 43
Study 11295624 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 0
Study 9445291 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow Triggering (FT)
Number of subjects: 8
Study 9445291 — intervention group
Group type: COMPARATOR
Intervention: Pressure Triggering (PT)
Number of subjects: 8
Study 7976152 — intervention group
Group type: EXPERIMENTAL
Intervention: Overhead radiant heater (ARAGONA Thermal Ceilings TM, CTCX, 1000 W)
Number of subjects: 35
Study 7976152 — intervention group
Group type: COMPARATOR
Intervention: Electric blanket (50 W)
Number of subjects: 35
Study 7976152 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital blanket
Number of subjects: 35
Study 2590271 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-aluminum-antacid (Mucal-Gel)
Number of subjects: 30
Study 2590271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1207281 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture‐O2‐N2O‐Analgesie (group I)
Number of subjects: 55
Study 1207281 — intervention group
Group type: COMPARATOR
Intervention: Neurolept‐Analgesia (group II)
Number of subjects: 55
Study 1207281 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study 31343761 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 protocolized telephone calls added to usual treatment
Number of subjects: 586
Study 31343761 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment only
Number of subjects: 586
Study 30848033 — intervention group
Group type: EXPERIMENTAL
Intervention: LY+TT223 (3 mg)
Number of subjects: 151
Study 30848033 — intervention group
Group type: EXPERIMENTAL
Intervention: LY+TT223 (2 mg)
Number of subjects: 151
Study 30848033 — intervention group
Group type: COMPARATOR
Intervention: LY‐only
Number of subjects: 151
Study 30848033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 28404455 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-anterior TDCS during iTBS
Number of subjects: 0
Study 28404455 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior-posterior TDCS during iTBS
Number of subjects: 0
Study 28404455 — intervention group
Group type: COMPARATOR
Intervention: Sham TDCS during iTBS
Number of subjects: 0
Study 25634940 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise specialist led lifestyle program targeting increased daily walking with individualized daily pedometer step goals for the first 3 months and brisk walking speed, along with substitution of low‐relative to high‐glycemic index foods over the next 3 months.
Number of subjects: 198
Study 25634940 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 198
Study 24034079 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day infusion of NBP followed by NBP capsule
Number of subjects: 573
Study 24034079 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day infusion of NBP followed by aspirin
Number of subjects: 573
Study 24034079 — intervention group
Group type: COMPARATOR
Intervention: 14-day infusion of ozagrel followed by aspirin
Number of subjects: 573
Study 21516550 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for MA dependence
Number of subjects: 526
Study 19079997 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic portal vein chemotherapy (PVC) after operation
Number of subjects: 51
Study 19079997 — intervention group
Group type: COMPARATOR
Intervention: Radical resection alone (control group)
Number of subjects: 51
Study 16623676 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased protein nitrogen appearance (0.2 g/kg/day)
Number of subjects: 190